May 2022

Allergy publishes the results of the first-in-human clinical trial (Phase 2) aimed at addressing the safety and optimal dose of the new mannan-house dust mite allergoid vaccines for subcutaneous and sublingual immunotherapy. The study, conducted in the Mediterranean coast of Spain and coordinated by Dr. Antonio Nieto as principal investigator, involved 13 allergy centers and 196 patients.
More info

March 2022

NEJM Evidence highlights in an Editorial the results of the clinical trial with MV140 recently published in that journal. MV140 showed its safety and efficacy in a randomized, double-blind, placebo-controlled, Phase 3 trial conducted in Spain and the United Kingdom.
More info

February 2022

The reduction of recurrent urinary tract infections after treatment with MV140 (UROMUNE) represents a significant health saving according to a study published in Urologia Internationalis. The savings have been calculated taking into account the healthcare costs and medication associated with this type of infection in Spain. This study was carried out at the Urology Department of the Albacete University Hospital Complex.
More info

January 2022

The results obtained with MV140 in women with recurrent urinary tract infections (UTIs) have been published in NEJM_Evidence. This is a randomized, placebo-controlled, Phase 3 clinical trial conducted in Spain and the United Kingdom to evaluate the safety and efficacy of MV140 in this condition.
More info

January 2022

Results published in Cell Reports show that MV130 protects against respiratory viral infections by inducing Trained Immunity. This type of immunity generates memory and depends on the "training" of Innate Immune System cells. Trained immunity involves epigenetic and metabolic changes that make trained cells more effective against infections, including viral infections.
More info

November 2021

According to the results published in Frontiers in Immunology, MV130 protects against experimental infection with SARS-CoV-2 in hACE2 transgenic mice. In addition, pretreatment with MV130 is shown to enhance the immunogenicity of candidate COVID-19 vaccines directed against viral protein S, enhancing both antibody and cell-specific responses.
More info

October 2021

Allergy publishes a study showing that allergoid-mannan conjugates confer tolerogenic properties to human macrophages. These cells have been described to play a relevant role in the induction of allergen-specific tolerance in sublingual immunotherapy models, so this study may help to better understand the immunological mechanisms of allergy vaccines based on these glycoconjugates.
More info

October 2021

The results of a clinical trial with MV140 in women suffering from recurrent urinary tract infections (UTI) have been presented at the ICS21 (International Continence Society) congress, as well as at the BAUS21 (British Association of Urological Surgeon), EAU21 (European Association of Urology) and AUA21 (American Urological Association). The study (phase III) has been carried out in several centers in Spain and the United Kingdom, including 240 patients in the active group and placebo.
More info

October 2021

According to a study published in Vaccine on a population of elderly people with recurrent urinary tract infections, prophylactic treatment with MV140 or with autovaccines made from a urine sample reduces the frequency of infections and improves the patients' quality of life. Comparatively, treatment with MV140 was superior to that obtained with autovaccines.
More info

September 2021

The first results with MV130 in COPD patients have been presented at the European Respiratory Society (ERS) congress, showing its efficacy in reducing the number and intensity of exacerbations associated with this disease. The phase 3 study has been conducted in 7 hospitals including 198 patients that were followed during 18 months.
More info